Dry powder inhaler market

[sportsrancho]

www.marketwatch.com/press-release/dry-powder-inhaler-market-global-industry-analysis-2012---2016-opportunity-assessment-2017---2026-2018-07-23

NEW YORK, July 23, 2018 /PRNewswire/ -- Managed care initiatives along with an aging population demographics is propelling growth of the home health care, and fuelling adoption of self-administered drug therapies. Inhaled medicine is therefore increasingly being discerned as patient-friendly. The inhaled therapy in general, and dry powder inhalers in particular are deemed to be well-positioned for capitalizing on these trends, and evolving as major drivers for future development of the pharmaceutical sector, and commercialization of therapeutic drugs related to respiratory disorders.

Read the full report: www.reportlinker.com/p05392458

Single-use Dry Powder Inhalers gaining Immense Traction owing to their Convenience and Easy Handling

There is a growing prevalence of chronic obstructive pulmonary disorders and asthma across the globe, particularly in developing nations, on the back of growing pollution levels and nicotine consumption. As these nations are cost-sensitive when it comes to expensive therapies regarding various respiratory diseases, demand for low-cost devices is surging across developing countries. In some places with no health insurance facilities, patients tend to share multi-use devices as the complete system become unaffordable for them. Single-use devices are therefore witnessing increased demand as they have the potential to overcome the aforementioned challenges and offer a hygienic & clean device. A major trend being witnessed in the market is the desire for convenience and easy handling of respiratory devices. Multiple dry powder inhalers are being purchased by patients with respiratory diseases as supplementary devices for different places such as cars, job sites, and homes. With single-use dry powder inhalers, patients are enabled to carry exact dose of inhalations required in blister packs, which in turn facilitates handling and convenience.

Some essential performance characteristics of the dry powder inhalers are related to performances at varying airflows, fine particle fraction content, and dose delivery. These characteristics vary in terms of powder formulations, thereby creating the requirement for fine tuning of devices or powder formulations or both combined in order to attain optimal performance. This requirement is relatively higher in the micro-dosing dry powder inhalers. This is further expected to pave opportunities for dry powder inhaler manufacturers based on innovations and advancements.

According to a report recently published by Future Market Insights, the global dry powder inhaler market is projected to register an average expansion through the forecast period, 2017 to 2026, in terms of volume. Worldwide sales of dry powder inhales will exceed 400,000 Mn units by 2026-end.

North America to Remain Largest Market for Dry Powder Inhaler

Presence of a robust healthcare infrastructure coupled with the technologically-advanced practice, mounting number of patients with respiratory disorders, stringent guidelines by regulatory bodies regarding medical devices associated with respiratory disorder therapeutics and relatively higher healthcare spending by the government are key factors that have made North America be the most lucrative market for dry powder inhalers. Sales of dry powder inhalers in North America will exceed 160,000 Mn units by 2026-end.

Chronic obstructive pulmonary disease will continue to be the fast-expanding application of dry powder inhalers. However, dry powder inhaler sales for application in asthma will remain relatively larger than those in chronic obstructive pulmonary disease.

Key Research Findings from FMI's Report

Multi-dose dry powder inhaler will continue to be dominant among products in the market

Hospital pharmacies will remain the fastest expanding distribution channel for dry powder inhalers

Competition Tracking

Leading players in the global market for dry powder inhalers are concentrating on developing new generation products. These market players are investing in R&D activities apropos to novel device architectures, powder formulations, and particle engineering. Development of enhanced particle properties, and efficient inhaler designs are expected to remain major strategies among the market participants. The report profiles key market participants, which include Astrazeneca Plc., 3M Company, GlaxoSmithKline Plc, Novartis AG, Cipla Ltd., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Chiesi Farmaceutici S.p.A., MannKind Corporation, and Vectura Group Plc.

[hellodolly]

Chronic obstructive pulmonary disease will continue to be the fast-expanding application of dry powder inhalers

Really?  COPD is more prevalent than diabetes that it would be the fastest expanding application for inhaled powder?  I actually thought that people with lung problems have been advised to reduce their exposure to inhaled powders?  If this isn't true, and COPD users are going to be prescribed inhaled powders, then why the label on Afrezza?  One person gets lung cancer (in a trial) that isn't, hasn't and can't be linked to Afrezza, is the only reason for that label?

[mnholdem]

Powders are composed of various ingredients. The FDA wants proof that the particulate and API formulation is safe. All new powder medications likely go through the same scrutiny.

[goyocafe]

Jul 24, 2018 8:22:17 GMT -5 mnholdem said:

Powders are composed of various ingredients. The FDA wants proof that the particulate and API formulation is safe. All new powder medications likely go through the same scrutiny.

Maybe if they add enough tobacco to Afrezza, they could sell it like cigarettes and avoid all this regulation. Insulin would just be another additive.

[mytakeonit]

So fast forward to 2026 ... Do I sell now at $2000 pps??? And why did I sell half my shares at $3 ?!!! Aarrrggghhhhh ...

[sayhey24]

Jul 24, 2018 5:45:17 GMT -5 hellodolly said:

Chronic obstructive pulmonary disease will continue to be the fast-expanding application of dry powder inhalers

Really?  COPD is more prevalent than diabetes that it would be the fastest expanding application for inhaled powder?  I actually thought that people with lung problems have been advised to reduce their exposure to inhaled powders?  If this isn't true, and COPD users are going to be prescribed inhaled powders, then why the label on Afrezza?  One person gets lung cancer (in a trial) that isn't, hasn't and can't be linked to Afrezza, is the only reason for that label?

COPD is on the label because Al was just trying to remove all excuses by the FDA to get afrezza approved.  He requested it be included on the label because there had been issues with Exubera and the FDA wanted afrezza to address Exubera issues.

However he knew from studies he did afrezza did not have the same issues.  Whats interesting in the below study is it was done using non-diabetics.

Whats also interesting is if Technosphere works so well with the COPDers you would think it would be the gold standard for these dry powder developments.  You would think this should be blockbuster news for MNKD, nope the pps was down again.

"Inhaled insulin preparations, such as Exubera, have been associated with a decreased rate and extent of absorption in
patients with COPD by up to 20–50% compared with those without COPD. A study assessing the pharmacoki-
netic profile of Technosphere insulin, when administered to nondiabetic patients with a diagnosis of COPD (n = 17)
and to those without COPD (n = 19), showed that neither mean peak insulin levels (34.7 and 39.5 µU/mL, respec-
tively; p = 0.285) nor median time to achieve insulin Cmax (15 and 12 min, respectively; p = 0.241) differed signifi-
cantly between groups. Mean insulin exposure from time 0 to 240 minutes postdose (AUC0-240)was 2037 and 2270
µU/mL•min (p = 0.469) for the respective groups. While this study was performed in a small cohort of patients
without diabetes, it provides some evidence that the kinetics of Technosphere insulin may be similar in those with
and those without a diagnosis of COPD."
www.researchgate.net/publication/44643382_A_Review_of_Inhaled_Technosphere_Insulin